Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia

OBJECTIVES: Chelating agents remain the mainstay in reducing the iron burden and extending patient survival in homozygous beta-thalassemia but adverse and toxic effects may increase with the institution and long term use of this essential therapy. This study aimed to estimate the incidence of defera...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Al-Khabori, Murtadha, Bhandari, Sunil, Al-Huneini, Mohammed, Al-Farsi, Khalil, Panjwani, Vinodh, Daar, Shahina
Format: Artigo
Sprache:Inglês
Veröffentlicht: OMJ 2013
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3628199/
https://ncbi.nlm.nih.gov/pubmed/23599881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5001/omj.2013.31
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge